Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Status:
Recruiting
Trial end date:
2023-11-04
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when
given together with pembrolizumab in treating patients with advanced gastrointestinal cancer
that has spread to other places in the body. XL888 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving
XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.